Structural Genomics Consortium and CHDI Foundation announce open-access collaboration to discover new drug targets for Huntington’s disease

The Structural Genomics Consortium (SGC) and CHDI Foundation have entered into a unique open-access research collaboration to discover and characterize new drug targets for Huntington’s disease (HD) using structural and chemical biology. In this first partnership of its kind, SGC and CHDI have explicitly agreed not to file for patents on any of the collaborative research and to make all reagents and knowledge available without restriction to the wider research community, including pharmaceutical, biotech, and academic research groups.

For more information, see http://media.utoronto.ca/media-releases/health-medicine/u-of-t-based-str...